What happens when a country finally removes the one excuse - lack of funding - that has explained away decades of underinvestment in research? India is about to find out.

India Finally Has the Money for a Research Leap. That Was Never the Hard Part.

For decades, India's underwhelming research output had a ready-made excuse: there simply wasn't enough money. At 0.64% of GDP, India's research spending has trailed the global average for so long that the figure stopped shocking anyone.

That excuse just got harder to make. Between the Anusandhan National Research Foundation's Rs 50,000 crore core allocation and the newly created Rs 1 lakh crore Research, Development and Innovation Fund, the state has now put real capital behind the ambition - patient capital, structured to survive longer than a single product cycle, aimed specifically at the pre-commercial research private companies have always been too risk-averse to fund themselves. TAN's position is that this removes the single strongest argument India's industry has used to explain its weak research record - and that industry should be judged accordingly from here.

The Design Is the Interesting Part

What makes the RDI Fund worth watching isn't just its size - it's the incentive structure underneath it. For every rupee a company commits to pre-commercial research through the foundation, it is expected to bring five to ten more of its own to actually commercialise the output.

That ratio is deliberate. It is not a subsidy that rewards spending; it is a catalyst that only pays off if the private partner follows through into the market. The foundation can absorb the riskiest, earliest-stage part of the bet.

It cannot make the rest of the climb for anyone.

The Precedent That Matters

Skeptics have reason to worry the money changes little. India's own patent record shows the country already files enormous numbers of patents while commercialising very few of them - proof that capital and paperwork alone don't create products.

But India has actually solved this exact problem before. When the WTO's intellectual property regime forced Indian pharmaceutical firms to abandon reverse-engineering in the 1990s, most observers expected the industry to be wiped out by multinational competition.

Instead, Indian firms invested in process chemistry and regulatory compliance and became the world's generic drug supplier. The constraint changed; the firms that survived were the ones that built real capability rather than waiting the crisis out.

What This Actually Demands of Industry The

ANRF removes the state's excuse. It does not remove industry's three remaining obligations: putting its own capital behind the public catalyst, choosing genuinely strategic technologies over safe incremental gains in captive markets and building the internal machinery - dedicated research units, corporate venture arms - that long-horizon research requires.

None of that can be legislated. Whether India's research spending finally moves is now a question about corporate behaviour, not government intent.